Investor Notes - Phillip Securities (HK) Ltd
Past Investor Notes  
Phillip Home Send to Friends Free Subscription Give Comments 中文版
22 Apr, 2026 (Wednesday)

            
GENSCRIPT BIO(1548)
Analysis:
Leveraging its proprietary gene synthesis technology alongside other technical expertise in life science research and applications, Genscript Biotech has successfully established three major platforms: Genscript Life Science Group, GenScript ProBio, and Bestzyme. Additionally, the Group holds a significant investment in Legend Biotech, an integrated cell therapy company.
As the core platform of the Group's biotechnology facilities, the Genscript Life Science Group provides global-scale integrated research services and products to empower biological discovery. Through its self-developed integrated platform, it offers complete solutions covering DNA synthesis, RNA synthesis, peptide synthesis, protein production, reagent antibody development, as well as life science instruments and consumables. These solutions support researchers in pharmaceutical companies, biotech firms, and academic institutions in accelerating the transition from research ideas to impactful biological discoveries. By lowering the barriers of speed, cost, and technical complexity in early-stage research, the Genscript Life Science Group plays a key role in driving the global development of next-generation biologics and advanced therapies.GenScript ProBio, a subsidiary of the Group, is a widely recognized global CRDMO that empowers innovators in biologics and Cell and Gene Therapy (CGT) by providing end-to-end solutions. Its integrated platform seamlessly combines discovery, development, and manufacturing services to optimize processes, shorten timelines, and increase the success rates of biologics and CGT projects. Bestzyme, also a subsidiary of the Group, operates in the industrial enzyme and synthetic biology product sectors. It utilizes advanced protein engineering technology to develop and produce innovative industrial enzymes, providing solutions for biofuels, food and beverage, distilling, starch, home care, textiles, animal feed industries, and functional proteins.
For the year ended December 31, 2025, the Group's overall revenue from continuing operations was approximately US$959.5 million, representing a significant year-on-year increase of 61.4%. Gross profit for the period was US$553.2 million, up 103.3%. The growth in revenue and gross profit was primarily attributable to: a substantial increase in licensing revenue (mainly from sub-licensing revenue generated by LaNova Medicines); sustained investment in commercial promotion coupled with a global brand transformation that enhanced brand awareness, particularly in Europe and the U.S.; the rapid growth of the gene-to-protein business driven by rising demand for AI-powered drug development and multi-antibody drug development; accelerating growth by successfully capturing the recovery in biologics CRDMO demand and market conditions; and the launch of innovative industrial enzyme products to continuously expand market share.(I do not hold the above stock.)
Strategy:
Buy-in Price: $14.00, Target Price: $15.50, Cut Loss Price: $13.30


HUA MEDICINE-B(2552)
Analysis:
Huamedicine is primarily engaged in investment and holding for the development and commercialization of oral new drugs for the treatment of type 2 diabetes. Its key product pipeline, Huatangling (Dorzagliatin or HMS5552), is a glucokinase activator (GKA) designed to control the progressive degenerative characteristics of diabetes by restoring blood glucose homeostasis in patients with type 2 diabetes, representing the world's first innovative dual-function GKA. Thanks to the termination of the contract liability after the collaboration with Bayer and the record-breaking sales of Huamedicine (over 4 million boxes sold, a 91% yoy increase, with revenue reaching 493 million yuan, a 93% yoy increase), Huamedicine achieved a pre-tax profit of 1.106 billion yuan in 2025, a 542% yoy growth. In 2026, the Company's commercialization team will further expand, planning to add over 100 more product representatives. In March 2026, Huatangling was officially approved for market launch in Hong Kong and will use Hong Kong as a hub to extend its reach to Southeast Asian markets such as Singapore, Malaysia, the Philippines, and Vietnam. Meanwhile, the second-generation GKA has initiated MAD studies in the U.S., with top-line data expected to be released by mid-year, followed by active discussions with MNCs to accelerate global commercialization.
Strategy:
Buy-in Price: $3.55, Target Price: $4.10, Cut Loss Price: $3.20



Geely 175 HK - Accelerating Overseas Expansion and Premiumisation Strategy

Company Profile

Geely is one of the leading enterprises in China's self-brand passenger vehicles manufacturers. The Company's products include six major brands, Geely, Lynk & Co, Zeekr, covering the A0 to C-class passenger vehicles market.

Investment Summary

26Q1 Sales Remained Largely Flat, with Premiumisation Strategy Showing Bright Spots. In the first quarter of 2026, Geely Auto delivered a cumulative 709.4 thousand vehicles, up 0.8% yoy, setting a new record high for the same period in history and regaining the top position among domestic brands. Among them, Geely brand's China Star recorded Q1 sales of 312 thousand units, down 5.5% yoy, while Galaxy sold 239 thousand units, down 8.0% yoy.

Among the sub-brands, the premium brands delivered standout performance: LYNK&CO sold 82 thousand units, up 12.5% yoy, while Zeekr sold 77 thousand units, up 86.1% yoy. The premium SUV model Zeekr 9X achieved a smooth ramp-up, with cumulative Q1 sales exceeding 20 thousand units and March sales surpassing 10 thousand units. It is the Company's first full-size premium SUV equipped with Super Hybrid technology, and also the first to feature the SEA AI Digital Chassis and the G-Pilot H9 intelligent assisted driving system.

With an average selling price of over RMB 530 thousand, it has significantly enhanced brand strength and the profitability potential following scale-up. We believe that the launch of flagship 9-series models, such as the LYNK&CO 900, Zeekr 9X and Galaxy M9, marks the beginning of a new chapter in the Company's premiumisation strategy in the SUV segment.

Explosive Growth in Exports

In overseas markets, Geely Auto recorded cumulative exports of 203 thousand units in Q1, up 125.7% yoy, far exceeding the industry's average growth rate of 56.7%, representing explosive growth and accounting for 28.6% of total sales. In the European market, the Company has completed brand layout in five core countries—Spain, Germany, the Netherlands, Belgium and Luxembourg. In the Southeast Asian market, Geely Xingyuan has commenced deliveries and is gradually advancing localised production.

In Latin America and the Middle East, the LYNK&CO and Zeekr brands are accelerating market penetration. The Company has provided 2026 full-year export sales guidance of no less than 640 thousand units, with a target of 750 thousand units, equivalent to yoy growth of 52.4% to 78.6%. Export business is expected to become the most important growth driver this year.

We believe that the rapid volume expansion and high profitability of overseas markets will help offset the slowdown in domestic sales and improve profit margins.

New Energy Vehicles Account for Over Half

Geely Auto's new energy transition is entering an accelerated phase. In Q1 2026, the Company's cumulative sales of new energy vehicles reached 369.1 thousand units, up 9% yoy, with the penetration rate rising to 52%, and further increasing to 55% in March alone. From a structural perspective, plug-in hybrid models contributed more incremental growth within Geely's new energy product portfolio, up 62% yoy and currently accounting for 44%, while pure electric models declined by 13% yoy, accounting for 56%.

Recent geopolitical conflicts in the Middle East have led to volatility in oil prices, which has objectively accelerated the global adoption of electric vehicles. In the long term, this trend benefits leading automakers with advantages in products, technology, cost, and supply chains. The Company's new energy vehicle segment is expected to achieve a favourable trajectory of simultaneous volume and profit growth.

Strong Performance Last Year, Core Net Profit up 36%

According to the Company's 2025 annual report, full-year revenue reached RMB 345,232 million, up 25.1% yoy; net profit attributable to the parent company was RMB 16,852 million, up 0.2% yoy. Excluding foreign exchange gains, impairment losses, and gains from the deemed disposal of subsidiaries in 2024, core net profit attributable to the parent company amounted to RMB 14.41 billion, up 36% yoy.

The strong performance was mainly driven by robust sales growth, which led to the release of scale effects, as well as optimisation of product mix and synergies from strategic integration. In 2025, the Company recorded cumulative sales of 3,024.6 thousand units, up 39.0% yoy, of which new energy vehicle sales reached 1,687.8 thousand units, up 90.0% yoy. Gross margin in 2025 was 16.61%, up 0.1 ppts yoy; core net profit margin attributable to the parent company increased to 4.2%, up 0.5 ppts yoy.

The rising sales mix of Zeekr contributed significantly to the improvement in overall gross margin. In terms of expense ratios, the sales/administration/R&D expense ratios were 5.92%/1.88%/5.1%, respectively, representing yoy changes of -0.04/-0.39/+0.14 ppts. This was mainly due to increased investment in the R&D of new models and platforms, as well as a lower capitalisation ratio of R&D expenses.

Looking ahead, as the One Geely strategy continues to deepen, the cost reduction effect from declining expense ratios—driven by technology sharing and cost optimisation—will continue to materialise.

Investment Thesis

We revised our financial forecast and target price to HKD 26.6, equivalent to 12.5/10.8/8.4x PE ratio in 2026/2027/2028, and we give the rating of Accumulate. Closing price as at 15 April.

Geely's PE Band trend

""

Source: Wind, Company, Phillip Securities Hong Kong Research

Financial

"Financial

(Closing price as at 15 April)


Download PDF version...




Recommendation on 22-4-2026
RecommendationAccumulate
Price on Recommendation Date$ 24.040
Suggested purchase priceN/A
Target Price$ 26.600
Writer Info
Zhang Jing
(Analyst)
Tel: (+ 86 021-6351 2939)
Email:
zhangjing@phillip.com.cn

Local Index
       Index    Change   Change%

World Index
       Index    Change   Change%
  

A-H spread
Stock Code H share
Price
A share
Price
H share
discount


Oversea Research Reports


Investment Service Centre



Enquiry : 2277 6666 OR investornotes@phillip.com.hk
If you cannot read this e-mail in the proper format, please click here to view the web version.

Information contained herein is based on sources that Phillip Securities (Hong Kong) Limited and/or its affiliates ( the “Group”) believe to be accurate. The Group does not bear responsibility for any loss occasioned by reliance placed upon the contents hereof. The Group (or its employees) may have interests in relevant investment products. For details of different products’ risks, please view the Risk Disclosures Statement on http://www.phillip.com.hk.

If you DO NOT wish to receive further marketing emails from us, please click HERE to opt-out.

版權所有, 翻印必究。

Copyright(C) 2026 Phillip Securities (HK) Ltd. All Rights Reserved.